研究拟评价多周期(大剂量)177Lu-DOTA-EB-TATE肽受体放射性核素治疗(PRRT)用于神经内分泌肿瘤(NETs)的安全性和有效性。共32例NET患者,随机分为3组:A组(1.17 ± 0.09 GBq/周期); B组(1.89 ± 0.53 GBq/周期); C组(3.97 ± 0...
Conclusions: A novel SST analogue, 177Lu-DOTA-EB-TATE, has the potential to be translated from bench to bedside for the targeted therapy of patients characterized by high uptake of SST analogues in metastatic lesions. 展开 DOI: 10.1158/1078-0432.CCR-20-3453 ...
近期研究者设想了一种个性化的PRRT方案[即P-PRRT试验(NCT02754297)],其中IA被调整为向肾提供规定的吸收剂量,目的是安全地增加肿瘤照射。纳入具有进展性和/或有症状神经内分泌肿瘤(NET)的初始PRRT患者接受177Lu-octreotate的4个周期诱导疗程(基于SPE...
Radiation safety of outpatient Lu-177-octreotate radiopeptide therapy of neuroendocrine tumors To demonstrate the safety of outpatient 7.8GBq (177)Lu-DOTA-tyr(3)-octreotate radiopeptide therapy of neuroendocrine tumors by measurement of radiation exp... PJ Calais,JH Turner - 《Annals of Nuclear ...
Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE.doi:10.2967/JNUMED.120.248658Qingxing LiuJie ZangHuimin SuiJiakun RenHua GuoHao WangRongxi WangOrit JacobsonJingjing Zhang...
Lu-177-DOTA-EB-TATE doses of 1.89 and 3.97 GBq/cycle were effective in tumor control and more effective than 1.17 GBq/cycle.Liu, QingxingZang, JieSui, HuiminRen, JiakunGuo, HuaWang, HaoWang, RongxiJacobson, OritZhang, JingjingCheng, YuejuanZhu, ZhaohuiChen, Xiaoyuan...
PURPOSE: The aim of this retrospective study was to determine whether patients with previous peptide receptor radionuclide therapy using high-activity (111)In-pentetreotide can be safely treated with (177)Lu-octreotate and whether addition of radiosensitising chemotherapy increases the toxicity of thi...
177Lu-DOTA-EB-TATE177Lu-DOTATATENeuroendocrine tumorTreatment Using 177Lu-DOTA-EB-TATE in Patients with Advanced Neuroendocrine Tumors (NCT03478358). URL: https://register.clinicaltrials.gov/prs/app/action/ViewOrUnrelease?uid=U0001JRW&ts=13&sid=S0007RNX&cx=y3yqv4...
An Evans blue-modified Lu-177-labeled octreotate (Lu-177-DOTA-EB-TATE) has an extended circulation in the blood, which may make the amino acid infusion unnecessary. The aim of this study was to evaluate the safety, biodistribution, and dosimetry of Lu-177-DOTA-EB-TATE with and without ...
Treatment Using 177Lu-DOTA-EB-TATE in Patients with Advanced Neuroendocrine Tumors (NCT03478358). URL: https://register.clinicaltrials.gov/prs/app/action/ViewOrUnrelease?uid=U0001JRW&ts=13&sid=S0007RNX&cx=y3yqv4doi:10.1007/s00259-019-04530-1...